Tenascin-C is an essential factor for neointimal hyperplasia after aortotomy in mice.
about
Tenascin-C in development and disease of blood vesselsPolymorphic variants in tenascin-C (TNC) are associated with atherosclerosis and coronary artery disease.Microsomal prostaglandin e2 synthase-1 modulates the response to vascular injuryAdvances in tenascin-C biology.Deletion of tenascin-C gene exacerbates atherosclerosis and induces intraplaque hemorrhage in Apo-E-deficient miceCell selective cardiovascular biology of microsomal prostaglandin E synthase-1.Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localizationTenascin-C deficiency in apo E-/- mouse increases eotaxin levels: implications for atherosclerosis.Type A dissection and chronic dilatation: tenascin-C as a key factor in destabilization of the aortic wall.Matricellular proteins: new molecular targets to prevent heart failure.Integrin signaling in atherosclerosis.The role of tenascin-C in tissue injury and tumorigenesis.Tenascin-C enhances crosstalk signaling of integrin αvβ3/PDGFR-β complex by SRC recruitment promoting PDGF-induced proliferation and migration in smooth muscle cells.Myeloid cell 5-lipoxygenase activating protein modulates the response to vascular injury.Distribution of myofibroblast and tenascin-C in cystic adventitial disease: comparison with ganglion.Bone Marrow-Derived Tenascin-C Attenuates Cardiac Hypertrophy by Controlling Inflammation.Internal Affairs: Tenascin-C as a Clinically Relevant, Endogenous Driver of Innate Immunity.
P2860
Q27027610-ED682FB5-83CC-498B-BF89-D89EFB79DF7EQ30422366-B5569B78-1046-4749-AC6A-9A1686571B92Q30557273-19F8C5E1-3B14-4D34-B5A2-48E59B0C282CQ35214557-93185F75-B7B0-4F6A-BDE0-AD751AE22610Q35937046-2E0A8AFC-07A6-42BE-8CEE-C932923C3393Q36537025-C113C70D-FBDE-41BE-A83D-6828BB687BD6Q36578825-A69AA1DF-F34A-4DEC-AFEB-BACB36BDD97CQ36753949-1FA02B76-1CAF-4086-8E55-8D894C309CA2Q37024218-B87982F9-8885-424A-9E26-7B236016AE93Q37925022-76008691-394A-47DB-9DFF-62E5245DBA85Q39155496-5E8D26C0-5D66-4737-A4BC-0C7713DD04A5Q39280466-F534BF89-FADC-42B8-A521-DD6F67E67EEEQ39500221-06A3A684-6077-47FA-9EF0-C0B6F255ED7CQ41760870-AD7596CF-12EB-4605-B0E9-1ACFD2996C7BQ43941861-ADB62C2D-0ADF-447B-9A9B-46B6E7AC6CC6Q46017590-580C71E3-4202-4CEE-A922-F64866799906Q49553693-BE57C02F-8108-47DF-8223-B9D6B4BF0F0B
P2860
Tenascin-C is an essential factor for neointimal hyperplasia after aortotomy in mice.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Tenascin-C is an essential factor for neointimal hyperplasia after aortotomy in mice.
@en
Tenascin-C is an essential factor for neointimal hyperplasia after aortotomy in mice.
@nl
type
label
Tenascin-C is an essential factor for neointimal hyperplasia after aortotomy in mice.
@en
Tenascin-C is an essential factor for neointimal hyperplasia after aortotomy in mice.
@nl
prefLabel
Tenascin-C is an essential factor for neointimal hyperplasia after aortotomy in mice.
@en
Tenascin-C is an essential factor for neointimal hyperplasia after aortotomy in mice.
@nl
P2093
P1476
Tenascin-C is an essential factor for neointimal hyperplasia after aortotomy in mice.
@en
P2093
Hideto Shimpo
Kazuya Fujinaga
Kiyohito Yamamoto
Koji Onoda
Kyoko Imanaka-Yoshida
Yasuhiro Sawada
P304
P356
10.1016/J.CARDIORES.2004.10.034
P577
2005-02-01T00:00:00Z